Medtronic (NYSE:MDT) Stock Price Down 0.5%

Medtronic plc (NYSE:MDT - Get Free Report) shares traded down 0.5% during mid-day trading on Monday . The stock traded as low as $81.30 and last traded at $81.30. 890,397 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 6,166,283 shares. The stock had previously closed at $81.69.

Wall Street Analysts Forecast Growth

MDT has been the subject of several analyst reports. Truist Financial lifted their price objective on Medtronic from $87.00 to $90.00 and gave the company a "hold" rating in a report on Wednesday, February 21st. Oppenheimer boosted their price target on Medtronic from $89.00 to $92.00 and gave the stock a "market perform" rating in a report on Wednesday, February 21st. Mizuho boosted their price target on Medtronic from $95.00 to $98.00 and gave the stock a "buy" rating in a report on Wednesday, February 21st. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $92.00 price target on shares of Medtronic in a report on Wednesday, February 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $94.91.

Medtronic Price Performance

The business has a 50-day simple moving average of $83.08 and a 200 day simple moving average of $81.56. The stock has a market cap of $108.57 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 2.66 and a beta of 0.78. The company has a current ratio of 2.30, a quick ratio of 1.71 and a debt-to-equity ratio of 0.46.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, February 20th. The medical technology company reported $1.30 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.04. Medtronic had a return on equity of 13.71% and a net margin of 13.00%. The firm had revenue of $8.09 billion for the quarter, compared to analyst estimates of $7.95 billion. During the same quarter in the previous year, the company posted $1.30 EPS. The business's revenue was up 4.7% on a year-over-year basis. On average, analysts forecast that Medtronic plc will post 5.2 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 12th. Investors of record on Friday, March 22nd were paid a dividend of $0.69 per share. The ex-dividend date of this dividend was Thursday, March 21st. This represents a $2.76 annualized dividend and a yield of 3.38%. Medtronic's dividend payout ratio is currently 87.90%.

Insider Buying and Selling

In related news, EVP Michael Marinaro sold 854 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $83.14, for a total transaction of $71,001.56. Following the completion of the sale, the executive vice president now owns 27,925 shares of the company's stock, valued at $2,321,684.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Sean Salmon sold 30,695 shares of the firm's stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $85.13, for a total transaction of $2,613,065.35. Following the completion of the sale, the executive vice president now owns 48,289 shares of the company's stock, valued at $4,110,842.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Marinaro sold 854 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $83.14, for a total value of $71,001.56. Following the completion of the sale, the executive vice president now directly owns 27,925 shares of the company's stock, valued at approximately $2,321,684.50. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medtronic

A number of hedge funds have recently added to or reduced their stakes in the company. CFO4Life Group LLC grew its stake in Medtronic by 41.0% in the first quarter. CFO4Life Group LLC now owns 4,135 shares of the medical technology company's stock valued at $360,000 after acquiring an additional 1,203 shares during the period. OLD Second National Bank of Aurora grew its stake in Medtronic by 3.9% in the first quarter. OLD Second National Bank of Aurora now owns 37,369 shares of the medical technology company's stock valued at $3,257,000 after acquiring an additional 1,411 shares during the period. Ballast Inc. grew its stake in Medtronic by 19.4% in the first quarter. Ballast Inc. now owns 8,454 shares of the medical technology company's stock valued at $737,000 after acquiring an additional 1,375 shares during the period. Kades & Cheifetz LLC grew its stake in Medtronic by 11.7% in the first quarter. Kades & Cheifetz LLC now owns 9,337 shares of the medical technology company's stock valued at $814,000 after acquiring an additional 980 shares during the period. Finally, Advisory Services Network LLC grew its stake in Medtronic by 16.9% in the first quarter. Advisory Services Network LLC now owns 80,197 shares of the medical technology company's stock valued at $6,989,000 after acquiring an additional 11,569 shares during the period. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.